Press Release: Xalud : Xalud Therapeutics' Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas

NEW YORK--(BUSINESS WIRE)--Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation through immune modulation, today announced that the Phase 2b study of XT-150 in patients with moderate-to-severe pain due to osteoarthritis (OA) of the knee has completed enrollment. Xalud has recently presented promising data from three of its previously completed Phase 1b/2a studies in the same indication in a poster presentation at t